You are currently viewing Pα+ Psychedelic Patent Analysis: April 2024

Pα+ Psychedelic Patent Analysis: April 2024

This Month:

  • General Overview
  • A CaaMTech & ASRI Collaboration
  • GH Research & Beckley Psytech: An Update
  • CaaMTech Grows Tryptamine Patent Portfolio
  • Atai Sees Two New Allowances to Support DMT Program


General Overview

We added 16 PCTs and 26 U.S. patent applications focused on psychedelics to our tracker in the month of April 2024. New entries came from the likes of Psilera, Aya Biosciences, Algernon, ASRI, Terran, GH Research, and more. 

(Subscribe or sign-in, below, to explore the interactive tables.)


A CaaMTech & ASRI Collaboration

In early April, a shared PCT (WO2024073356) from psychedelic drug developers the Alexander Shulgin Research Institute (ASRI) and CaaMTech was published. The PCT appears to be the first IP product to emerge from a collaboration between the two parties that was announced nearly two years ago.

Since its inception, CaaMTech has worked to synthesise and characterise solid forms of dozens of psychedelics. The company’s drug discovery work, largely focused on tryptamines, has supported the creation of a patent portfolio consisting of around three dozen PCTs and many more national stage entries. In addition to its intellectual property pursuits, CaaMTech’s fundamental science efforts have translated into more than two dozen publications since 2019.

At the same time, since its founding in 2021, ASRI has worked to develop and advance its own portfolio of novel psychedelics. A number of the company’s PCT have published since early 2023 (WO2024006226WO2023034645WO2023028091 & WO2023028092), and more recently the company’s first patent U.S. application (US 18/549,374) was allowed, which received fast track examination under the Patent Prosecution Highway.

Subscribe or sign in to continue reading…

PA+ Header Psychedelic Alpha

The Psychedelic Patent Analysis: A Pα+ Subscriber Benefit

Each month, we provide an interactive database of psychedelic patents that were granted, allowed, abandoned, rejected or that had responses filed.

Patent Analysis

We then provide detail and analysis on a handful of specific cases, or one deep dive.

Our monthly Psychedelic Patent Analysis is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

button

Join Button

Companies, organisations and candidates mentioned in this analysis: DemeRx, Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, CLE-100, Gilgamesh Pharmaceuticals, MindMed, Awakn Life Sciences, and others.